Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Y.HoggN
Ianalumab, a fully human monoclonal antibody targeting BAFF-R, is under investigation in a randomized, double-blind phase III trial to assess its efficacy and safety in SLE patients (ClinicalTrials.gov Identifier: NCT05624749) (137)
This review paper summarizes the research findings for NAD+ boosters and brain health, highlighting positive benefits for cognitive function and brain aging in animal models
10.1146/annurev.nutr.24.012003.132418 7
US$ 20.48
US$ 20.10
US$ 25.30
US$ 22.03
US$ 23.41
US$ 22.45
